An RNA-seq study in Friedreich ataxia patients identified hsa-miR-148a-3p as a putative prognostic biomarker of the disease

Abstract Friedreich ataxia (FRDA) is a life-threatening hereditary ataxia; its incidence is 1:50,000 individuals in the Caucasian population. A unique therapeutic drug for FRDA, the antioxidant Omaveloxolone, has been recently approved by the US Food and Drug Administration (FDA). FRDA is a multi-sy...

Descrición completa

Detalles Bibliográficos

Principais autores:	Chiara Vancheri, Andrea Quatrana, Elena Morini, Caterina Mariotti, Alessia Mongelli, Mario Fichera, Alessandra Rufini, Ivano Condò, Roberto Testi, Giuseppe Novelli, Florence Malisan, Francesca Amati
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2024-05-01
Series:	Human Genomics
Assuntos:	microRNA RNA-seq Biomarkers Friedreich ataxia Frataxin
Acceso en liña:	https://doi.org/10.1186/s40246-024-00602-y
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!